Sign In
Buy KPTI
$9.00
-0.230 (-2.49%)
At Close: Jun 03, 2026
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Increased to $26.00 by Analysts at Wedbush
05:34am, Wednesday, 24'th Jun 2020
Karyopharm Therapeutics (NASDAQ:KPTI) had its price target increased by Wedbush from $18.99 to $26.00 in a research report sent to investors on Tuesday morning, BenzingaRatingsTable reports. They curr
XPOVIO® (selinexor) Now Approved for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Available from Onco360
12:00am, Wednesday, 24'th Jun 2020
Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by Karyopharm to be a specialty pharmacy partner for XPOVIO® (selinexo
Karyopharm's Xpovio Gets FDA Accelerated Approval for DLBCL
03:50pm, Tuesday, 23'rd Jun 2020
Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in relapsed or refractory diffuse large B-cell lymphoma.
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (NASDAQ: KPTI) and Pfizer (NYSE: PFE) - Markets
10:27am, Tuesday, 23'rd Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Atara Biotherapeutics (ATRA) - Markets
10:14am, Tuesday, 23'rd Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics
KARYOPHARM THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K) | MarketScreener
08:36pm, Monday, 22'nd Jun 2020
Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved oral XPOVIO® (selinexor), the Company�
Pedidos de seguro-desemprego sobem 43% em maio no Amapá; são mais de 2,2 mil na pandemia
05:36am, Monday, 22'nd Jun 2020
Benefício pode ser requerido por trabalhadores dispensados sem justa causa.
The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions
06:53pm, Sunday, 21'st Jun 2020
Biotech stocks rebounded along with the broader market in the week ended June 19. The week was a busy one from the perspective of PDUFA dates, with the FDA issuing approvals for Merck & Co., Inc. (NYS
The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions
12:00am, Sunday, 21'st Jun 2020
Biotech stocks rebounded along with the broader market in the week ended June 19. The week was a busy one from the perspective of PDUFA dates, with the FDA issuing approvals...
Stocks To Watch: Nike, Apple, Ford And Stressed Banks
08:39am, Saturday, 20'th Jun 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
Karyopharm Therapeutics (NASDAQ:KPTI) Rating Increased to Hold at BidaskClub
01:18am, Friday, 19'th Jun 2020
Karyopharm Therapeutics (NASDAQ:KPTI) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, BidAskClub rep
Karyopharm Therapeutics Inc (KPTI): Hedge Funds Taking Some Chips Off The Table
07:34pm, Thursday, 18'th Jun 2020
In this article you are going to find out whether hedge funds think Karyopharm Therapeutics Inc (NASDAQ:KPTI) is a good investment right now. We like to check what the smart money thinks first before
In Africa, those who beat the virus continue to live under its cloud
07:00pm, Thursday, 18'th Jun 2020
Kinshasa, DR Congo | AFP | As coronavirus cases accelerate in Africa, those who recover from the virus find that their struggle is not over as denial of the disease and stigmatisation run deep across
